Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • February 2022 (Revised November 2022)
  • Case
  • HBS Case Collection

Nuritas

By: Mitchell Weiss, Satish Tadikonda, Vincent Dessain and Emer Moloney
  • Format:Print
  • | Language:English
  • | Pages:19
ShareBar

Abstract

Nora Khaldi had built a technology “to unlock the power of nature” in the service of extending human lifespan and improving health, and now in April 2020 was debating telling her Board of Directors she wanted to put on ice some of her discoveries. Nuritas, the company she founded in 2014, leveraged artificial intelligence (AI) to find specific peptides―short chains of amino acids―among the trillions that exist in nature and target them for preventing or treating the onset of disease and preserving health for longer. Khaldi worried that getting certain products to market was taking too long and about the potential distraction caused by doing too many projects to serve very distinct industries. Underlying this was her concern that cash would run short if they tried to do it all. She weighed shutting down Nuritas’s promising early-stage pharmaceutical projects―including one aimed at treating Glioblastoma, an aggressive brain cancer―to focus on consumer-oriented approaches, like a supplement to improve muscle health and reduce the physical signs of aging. Khaldi contemplated telling her team to cease most of their pharmaceutical work, at least for the time being, and eliminate roles linked to that part of the business.

Keywords

Cash Burn; Cash Flow Analysis; Pharmaceutical Companies; Founder; Artificial Intelligence; AI; Entrepreneurship; Health Testing and Trials; Health Care and Treatment; Decision Making; Market Entry and Exit; AI and Machine Learning; Pharmaceutical Industry

Citation

Weiss, Mitchell, Satish Tadikonda, Vincent Dessain, and Emer Moloney. "Nuritas." Harvard Business School Case 822-080, February 2022. (Revised November 2022.)
  • Educators
  • Purchase

About The Authors

Mitchell B. Weiss

Entrepreneurial Management
→More Publications

Satish K. Tadikonda

Entrepreneurial Management
→More Publications

Related Work

    • February 2022 (Revised November 2022)
    • Faculty Research

    Nuritas

    By: Mitchell Weiss, Satish Tadikonda, Vincent Dessain and Emer Moloney
Related Work
  • Nuritas By: Mitchell Weiss, Satish Tadikonda, Vincent Dessain and Emer Moloney
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.